TSA provides support and information to everyone for free. Please help us keep doing so, by becoming a member of TSA.

mTOR inhibitors for epilepsy in children with TSC

About this study

Epilepsy is one of the most common neurological manifestations of TSC (Tuberous Sclerosis Complex), affecting up to 85–95% of children with the condition. While anti-seizure medications are the first line of treatment, some children continue to experience seizures despite trying multiple medications. 

Changes in the mTOR pathway, which regulates cell growth and development, are central to TSC. Mutations in the TSC1or TSC2 genes result in overactivity of this pathway. mTOR inhibitors, including sirolimus and everolimus, target this pathway and are already used to treat several manifestations of TSC. 

This study investigated whether adding sirolimus or everolimus to existing epilepsy treatment could reduce seizure frequency in children with TSC. It also examined the safety of these medications and whether outcomes differed depending on the age at which seizures first developed.

How the study was conducted

Researchers from the Children’s Hospital of Chongqing Medical University in China reviewed the medical records of children with TSC who received care at the hospital between July 2018 and June 2023. The epilepsy treatment analysis included 104 children with TSC and epilepsy, who were divided into two groups:

  • mTOR inhibitor group: 53 children who received sirolimus or everolimus alongside their existing epilepsy treatment.
  • No mTOR inhibitor group: 51 children who received epilepsy treatment without an mTOR inhibitor.

The researchers compared changes in seizure frequency between the two groups. 

A reduction in seizure frequency of at least 50% was considered a positive treatment response.  

They also examined whether outcomes differed between children whose seizures first developed at or before two years of age and those whose seizures began after two years of age. 

A separate safety analysis examined 98 children treated with mTOR inhibitors, looking at reported adverse effects and changes in blood test results.

Outcomes of the study

At the last follow-up, 81.1% of children receiving an mTOR inhibitor alongside their existing epilepsy treatment had a reduction in seizure frequency of at least 50%, compared with 54.9% of children who did not receive an mTOR inhibitor. The study also found that seizure reduction was more likely with longer treatment duration. 

In the safety analysis, 49% of children in the mTOR inhibitor group experienced at least one adverse effect, most commonly mouth ulcers, elevated cholesterol levels and upper respiratory tract infections. Most adverse effects were mild to moderate, although a small number of children experienced a more serious adverse effect.

Conclusions of the study

The researchers concluded that mTOR inhibitors may be useful additional treatments for epilepsy in children with TSC, particularly for those who continue to experience seizures despite existing treatment. 

Both sirolimus and everolimus were associated with improvements in seizure frequency, with benefits observed in children whose seizures began both before and after two years of age. The findings also suggest that longer treatment duration may be associated with better seizure outcomes. 

While adverse effects were relatively common, most were mild and manageable. The researchers emphasised that further studies are needed to identify which children are most likely to benefit from mTOR inhibitor treatment.

Implications of the study

These findings add to the growing body of research exploring the role of mTOR inhibitors in managing TSC-associated epilepsy. The findings suggest that mTOR inhibitors may be worth further investigation in children with seizure onset before two years of age, a group in which epilepsy can be particularly difficult to manage.  However, there are some important limitations to consider. This was a retrospective study conducted at a single hospital in China, involving a relatively small number of children. The researchers also did not analyse treatment responses according to specific seizure types, such as focal seizures or infantile spasms. 

Further studies are needed to better understand which children are most likely to benefit, the ideal duration of treatment and the longer-term safety of these medications. For the TSC Community, the study highlights the continuing importance of research into targeted treatments that address the underlying biology of TSC, rather than focusing solely on managing individual symptoms.

DISCLAIMER

This information is intended to provide some insights into recent TSC-related research.  It is not intended to, and it should not, constitute medical or other advice.  Readers are warned not to take any action without first seeking medical advice.

Ding R, Meng L, Hong S, et al. (2026). Adjunctive antiepileptic efficacy and safety study of mTOR inhibitors in children with tuberous sclerosis complex. Seizure: European Journal of Epilepsy, 138, 84–92. https://doi.org/10.1016/j.seizure.2026.04.002